Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anemia
Community Oncology explores pitched debate over anemia-fighting drugs
July 10th, 2007
Elsevier’s Community Oncology takes an in-depth look at the charge that ESAs, generally considered vital to cancer patients’ quality of life, are overprescribed for profit. Scientists, oncologists, and critics of oncologists are in a heated debate now over the use of ESAs, or erythropoiesis-stimulating agents—drugs that fight anemia by boosting levels of oxygen-carrying red blood cells and the protein hemoglobin. Many cancer patients, suffering from fatigue and symptomatic anemia as side effects of their disease and its treatment, are prescribed ESAs—also known as EPO (epoetin alfa, or Procrit) and DARB (darbepoetin alfa, or Aranesp). New data—mostly from studies of...
Source: Drug Law Weekly (2007-07-10)
|
